Squamous cell carcinoma in situ. Photo by Klaus D. Peter via Wikimedia Commons Findings from a preclinical study show a topical cream that blocks the immune-suppressing enzyme LSD1 suppressed tumour growth in two models of cutaneous squamous cell carcinoma (cSCC). The study, published in the  Journal of Clinical Investigation ,  describes how the cream, developed by researchers at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, prevents LSD1

Global maps of age-standardized incidence rate attributable to (A) cutaneous melanoma, (B) squamous cell carcinoma, and (C) basal cell...

The Dermatology Association of Radiation Therapy (DART), a U.S. national non-profit medical society, has published new clinical...

New research from the Mayo Clinic suggests patients with lower-limb lymphedema had twice the risk of developing skin cancer than patients...

New findings from the University of Gothenburg in Sweden show that methotrexate (MTX) use is associated with a higher risk of skin cancer...

A Finnish study of nearly 500 people who had an increased risk of skin cancer revealed fewer cases of melanoma in those who took vitamin...

New research by a Massachusetts General Hospital-led team indicates that simple laser treatments to the skin may help to prevent the...

In a study of RAS gene mutations in squamous cell carcinoma, researchers have found that a single mutated gene in an otherwise healthy...